Alfredo Jose Mena Lora
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alfredo Jose Mena Lora has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
Eden Takhsh
Saint Anthony Hospital, Chicago, IL, USA
12 shared publicationsCandice Krill
Saint Anthony Hospital, Chicago, IL, USA
9 shared publicationsSusan C. Bleasdale
Division of Infectious Diseases, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
9 shared publicationsMirza Ali
Saint Anthony Hospital, Chicago, IL, USA
7 shared publications- Scott Borgetti
University of Illinois Hospital and Health Sciences System, Chicago, IL 60612, USA
7 shared publications Rodrigo Burgos
University of Illinois at Chicago, Chicago, IL, USA
6 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Artificial Intelligence in Fellowship Leadership: Practical Applications for Recruitment, Education, and Program Management
Fellowship program directors (PDs) oversee a broad range of responsibilities spanning recruitment, education, mentorship, evaluation, scheduling, accreditation, and program administration. These activities require substantial time and coordination, often with limited resources. Artificial intelligence (AI) offers an opportunity to support PD workflows. In this review, we describe practical applications of AI in fellowship leadership using real-world examples from an Infectious Diseases fellowship program. Applications include recruitment marketing, applicant review and summarization, multilingual global health education, individualized board preparation, and scheduling optimization. We also discuss governance considerations and lessons from other industries that have successfully integrated AI into complex workflows. AI can expand the PD toolkit and support more efficient program management, potentially allowing greater focus on mentorship, education, and program development. Further evaluation is needed to assess its effects on efficiency, cost, educational outcomes, and recruitment.
- 12 November 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
Open AccessArtificial Intelligence in Fellowship Leadership: Practical Applications for Recruitment, Education, and Program Management
Fellowship program directors (PDs) oversee a broad range of responsibilities spanning recruitment, education, mentorship, evaluation, scheduling, accreditation, and program administration. These activities require substantial time and coordination, often with limited resources. Artificial intelligence (AI) offers an opportunity to support PD workflows. In this review, we describe practical applications of AI in fellowship leadership using real-world examples from an Infectious Diseases fellowship program. Applications include recruitment marketing, applicant review and summarization, multilingual global health education, individualized board preparation, and scheduling optimization. We also discuss governance considerations and lessons from other industries that have successfully integrated AI into complex workflows. AI can expand the PD toolkit and support more efficient program management, potentially allowing greater focus on mentorship, education, and program development. Further evaluation is needed to assess its effects on efficiency, cost, educational outcomes, and recruitment.
- Open Access
- 17 July 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (9) , 962-965
Sustained reduction in blood culture utilization following a crisis-driven diagnostic stewardship intervention
Following a global 2024 blood culture bottle shortage, we implemented a multidisciplinary stewardship intervention to reduce utilization. Upon supply normalization in 2025, a durable 34.8% reduction in utilization was maintained without increasing sepsis-related mortality, demonstrating that crisis-driven shifts can successfully establish a sustainable “new steady state.”
- 17 July 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (9) , 962-965
Open AccessSustained reduction in blood culture utilization following a crisis-driven diagnostic stewardship intervention
Following a global 2024 blood culture bottle shortage, we implemented a multidisciplinary stewardship intervention to reduce utilization. Upon supply normalization in 2025, a durable 34.8% reduction in utilization was maintained without increasing sepsis-related mortality, demonstrating that crisis-driven shifts can successfully establish a sustainable “new steady state.”
- Open Access
- 6 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e204
A nationwide survey of infection prevention and control and high-level disinfection and sterilization practices in the Dominican Republic
Healthcare-associated infections (HAIs) are often preventable and cause significant morbidity and mortality. There is a paucity of data on HAIs in low- and middle-income countries. This study surveyed Dominican Republic hospitals, revealing that 60% had Infection Prevention, and Control (IPC) programs, but gaps remain in IPC committees, training, data tracking, and reporting.
- 6 July 2026
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 6 (1) , e204
Open AccessA nationwide survey of infection prevention and control and high-level disinfection and sterilization practices in the Dominican Republic
Healthcare-associated infections (HAIs) are often preventable and cause significant morbidity and mortality. There is a paucity of data on HAIs in low- and middle-income countries. This study surveyed Dominican Republic hospitals, revealing that 60% had Infection Prevention, and Control (IPC) programs, but gaps remain in IPC committees, training, data tracking, and reporting.
- Open Access
- 23 June 2026
- Vol. 9 (3)
Comparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials
To compare differences in risk factors and 90-day mortality prediction from 2 machine learning (ML) models with a previously published non-ML model and investigate their validity in an external cohort. Prospectively collected data from 2 separate randomized controlled trial (RCT) cohorts from 2020 to 2021, the Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Trial (derivation and internal validation cohort) and the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Trial (external validation cohort) were used. Data were collected from 114 sites in 10 countries (TICO/ACTIV-3) and 63 sites in 11 countries (ITAC). A ML pipeline including 5 classification models, and 1 survival model was used for risk factor identification and clinical outcome prediction. Risk factors were compared between a ML-based classification model, a ML-based survival model and a previously published Cox model. Performance of the ML-based classification model was compared across TICO/ACTIV-3 and ITAC. A total of 2625 (TICO/ACTIV-3) and 579 (ITAC) adults hospitalized for COVID-19 were included. Some overlap of risk factors was identified across models. Five were identified in all models, 3 only in ML models, and 4 only in the non-ML model. The ML model showed good predictive performance in TICO/ACTIV-3. Internal validation showed no overfitting. Lower model performance was observed in ITAC (−15.8%), but performance remained above chance level. Differences in methods for risk factor identification using ML and non-ML complicates the comparison of results derived from each approach, but using multiple approaches may unveil overlooked risk factors. Risk factor identification may benefit from integrating both ML and non-ML methods, but external validation is necessary, even in RCTs.
- 23 June 2026
- Vol. 9 (3)
Open AccessComparing risk factors in severe COVID-19 using machine learning and non-machine learning methods: analysis from 2 international randomized controlled trials
To compare differences in risk factors and 90-day mortality prediction from 2 machine learning (ML) models with a previously published non-ML model and investigate their validity in an external cohort. Prospectively collected data from 2 separate randomized controlled trial (RCT) cohorts from 2020 to 2021, the Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) Trial (derivation and internal validation cohort) and the Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) Trial (external validation cohort) were used. Data were collected from 114 sites in 10 countries (TICO/ACTIV-3) and 63 sites in 11 countries (ITAC). A ML pipeline including 5 classification models, and 1 survival model was used for risk factor identification and clinical outcome prediction. Risk factors were compared between a ML-based classification model, a ML-based survival model and a previously published Cox model. Performance of the ML-based classification model was compared across TICO/ACTIV-3 and ITAC. A total of 2625 (TICO/ACTIV-3) and 579 (ITAC) adults hospitalized for COVID-19 were included. Some overlap of risk factors was identified across models. Five were identified in all models, 3 only in ML models, and 4 only in the non-ML model. The ML model showed good predictive performance in TICO/ACTIV-3. Internal validation showed no overfitting. Lower model performance was observed in ITAC (−15.8%), but performance remained above chance level. Differences in methods for risk factor identification using ML and non-ML complicates the comparison of results derived from each approach, but using multiple approaches may unveil overlooked risk factors. Risk factor identification may benefit from integrating both ML and non-ML methods, but external validation is necessary, even in RCTs.
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 59-69
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial
Background: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. Methods: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the days to recovery scale through day 60 (DRS-60), analyzed using a Van Elteren test. Results: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (P = .19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; P < .001). There was no difference in secondary clinical outcomes or prespecified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. Conclusions: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared with earlier periods in the COVID-19 pandemic and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.
- 22 April 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , 59-69
Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial
Background: Antivirals remain an important treatment strategy for persons who experience severe and life-threatening COVID-19. Ensitrelvir is an oral 3CL protease inhibitor with potent antiviral activity. Methods: We conducted an international randomized, placebo-controlled trial of ensitrelvir with standard of care (SOC) among adults hospitalized for COVID-19. The primary outcome was clinical recovery assessed by the days to recovery scale through day 60 (DRS-60), analyzed using a Van Elteren test. Results: From 2023 to 2025, 589 participants received blinded study treatment (293 ensitrelvir and 296 placebo). Median age was 69 years, 49% were female, 68% were White, and SOC commonly included corticosteroids (61% and 54%) and remdesivir (62% and 60%) in ensitrelvir and placebo groups, respectively. Median DRS-60 category was 6 (IQR: 3-15) in the ensitrelvir and 5.5 (IQR: 3-12) in the placebo group (P = .19), and the OR was 0.82 (95% CI: 0.62-1.09) for a better DRS-60 category with ensitrelvir. Ensitrelvir participants had lower detectable viral antigen in plasma at Day 5 (13.4% vs 25.1%; P < .001). There was no difference in secondary clinical outcomes or prespecified safety outcomes, though the mortality rate was 6.1% vs 4.4% and the frequency of hemorrhagic events was 3.4% vs 0.3% among ensitrelvir and placebo groups, respectively. Conclusions: Ensitrelvir treatment did not improve clinical recovery in addition to SOC for adults hospitalized for COVID-19. The lower illness severity in the Omicron era compared with earlier periods in the COVID-19 pandemic and high use of remdesivir and corticosteroids, may have contributed to the lack of clinical benefit.
- Open Access
- 25 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Bridging the Gap: A Needs Assessment of Resources and Support for International Medical Graduates Navigating Visa-related Career Decisions in Infectious Diseases
International medical graduates (IMGs) in infectious disease encounter distinct career and immigration-related barriers during training. We conducted a needs-assessment survey to better understand challenges IMGs face. Results underscore the importance of developing targeted guidance and structured support for IMGs and program leadership.
- 25 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessBridging the Gap: A Needs Assessment of Resources and Support for International Medical Graduates Navigating Visa-related Career Decisions in Infectious Diseases
International medical graduates (IMGs) in infectious disease encounter distinct career and immigration-related barriers during training. We conducted a needs-assessment survey to better understand challenges IMGs face. Results underscore the importance of developing targeted guidance and structured support for IMGs and program leadership.
- Open Access
- 6 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e251
Lessons learned from a diagnostic stewardship intervention in response to a blood culture bottle supply shock
Faced with a national blood culture bottle shortage, our institution formed a multidisciplinary stewardship team and implemented policy changes. This reduced orders by 60%, potentially saving $145,000 monthly, while maintaining stable in-hospital sepsis mortality rates.
- 6 October 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e251
Open AccessLessons learned from a diagnostic stewardship intervention in response to a blood culture bottle supply shock
Faced with a national blood culture bottle shortage, our institution formed a multidisciplinary stewardship team and implemented policy changes. This reduced orders by 60%, potentially saving $145,000 monthly, while maintaining stable in-hospital sepsis mortality rates.
- Open Access
- 29 August 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e196
A nationwide survey of antimicrobial stewardship infrastructure and CDC core elements in the Dominican Republic
Antimicrobial resistance is a global threat, and antimicrobial stewardship programs (ASP) are vital to curb resistance. A survey of 20 Dominican Republic hospitals revealed ASPs were absent in 50% and compliance with CDC core elements varied, highlighting significant challenges and areas of opportunity in implementing effective stewardship in resource-limited settings.
- 29 August 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e196
Open AccessA nationwide survey of antimicrobial stewardship infrastructure and CDC core elements in the Dominican Republic
Antimicrobial resistance is a global threat, and antimicrobial stewardship programs (ASP) are vital to curb resistance. A survey of 20 Dominican Republic hospitals revealed ASPs were absent in 50% and compliance with CDC core elements varied, highlighting significant challenges and areas of opportunity in implementing effective stewardship in resource-limited settings.
- Open Access
- 26 August 2025
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 153, 1-12
Candidemia in the Dominican Republic: species distribution, resistance, clinical characteristics, and outcomes at a tertiary care hospital
Bloodstream infections (BSIs) caused by Candida are a significant cause of morbidity and mortality. Geographical variations exist in the epidemiology of candidemia, with a paucity of data in the many low- and middle-income countries. We performed a retrospective study of candidemia from 2017 to 2022 at a 289-bed teaching hospital in the Dominican Republic (DR). A total of 197 cases were reviewed. Overall mortality rate was 49.2%. Age and vasopressor use were associated with mortality. The most prevalent Candida species were C. tropicalis and C. parapsilosis. C. albicans was 12% resistance to amphotericin B. These findings underscore the importance of understanding local epidemiology and may help inform empiric therapy and the development of treatment guidelines in the DR.
- 26 August 2025
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 153, 1-12
Open AccessCandidemia in the Dominican Republic: species distribution, resistance, clinical characteristics, and outcomes at a tertiary care hospital
Bloodstream infections (BSIs) caused by Candida are a significant cause of morbidity and mortality. Geographical variations exist in the epidemiology of candidemia, with a paucity of data in the many low- and middle-income countries. We performed a retrospective study of candidemia from 2017 to 2022 at a 289-bed teaching hospital in the Dominican Republic (DR). A total of 197 cases were reviewed. Overall mortality rate was 49.2%. Age and vasopressor use were associated with mortality. The most prevalent Candida species were C. tropicalis and C. parapsilosis. C. albicans was 12% resistance to amphotericin B. These findings underscore the importance of understanding local epidemiology and may help inform empiric therapy and the development of treatment guidelines in the DR.
- Open Access
- 30 June 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e140
A comparative study of antimicrobial prescribing practices for common infectious syndromes among physicians and nurse practitioners in a safety-net hospital
Antimicrobial prescribing differences between physicians and nurse practitioners (NPs) remain poorly characterized. We compared prescribing practices at a safety-net hospital. NPs adhered more to pneumonia guidelines, while physicians had better adherence for abdominal and urinary infections. Ineffective therapy was more common for NPs. These gaps highlight important stewardship opportunities.
- 30 June 2025
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 5 (1) , e140
Open AccessA comparative study of antimicrobial prescribing practices for common infectious syndromes among physicians and nurse practitioners in a safety-net hospital
Antimicrobial prescribing differences between physicians and nurse practitioners (NPs) remain poorly characterized. We compared prescribing practices at a safety-net hospital. NPs adhered more to pneumonia guidelines, while physicians had better adherence for abdominal and urinary infections. Ineffective therapy was more common for NPs. These gaps highlight important stewardship opportunities.